79 results match your criteria: "Adana Dr. Turgut Noyan Research and Treatment Center[Affiliation]"
Prostate
December 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey.
Acta Oncol
November 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey.
Prostate
November 2024
Department of Radiation Oncology, Adana Dr Turgut Noyan Research and Treatment Center, Baskent University Faculty of Medicine, Adana, Turkey.
Strahlenther Onkol
November 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkey.
Eur J Nucl Med Mol Imaging
October 2024
Faculty of Medicine, Department of Radiation Oncology, Baskent University, Ankara, Turkey.
Prostate
November 2024
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Purpose: To assess the early metabolic response of the primary tumor using Gallium-68 (Ga)-labeled-prostate-specific membrane antigen positron emission tomography (Ga-PSMA-PET/CT), as well as the relationship between PSMA change in the primary tumor and PSA response after definitive radiotherapy (RT), either alone or in combination with androgen deprivation therapy (ADT) in intermediate risk prostate cancer (IR-PCa) patients.
Methods: The clinical data of 71 IR-PCa patients treated with RT alone (36 patients, 50.7%) or RT and ADT (35 patients, 49.
Strahlenther Onkol
November 2024
Faculty of Medicine, Department of Radiation Oncology, Baskent University, Ankara, Turkey.
Purpose: This study sought to determine the predictive and prognostic value of clinicopathological parameters and neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and hemoglobin (Hgb) level in predicting recurrence patterns and locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS) in cervical cancer patients receiving definitive chemoradiotherapy (ChRT).
Methods: This study included 261 cervical cancer patients treated with ChRT. The primary endpoints were the predictors of local recurrence (LR) and distant metastasis (DM), whereas the secondary endpoints were LRFS and DMFS.
Radiother Oncol
October 2024
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address:
Purpose: This study investigated imaging biomarkers derived from PSMA-PET acquired pre- and post-metastasis-directed therapy (MDT) to predict 2-year metastasis-free survival (MFS), which provides valuable early response assessment to improve patient outcomes.
Materials/methods: An international cohort of 117 oligometastatic castration-sensitive prostate cancer (omCSPC) patients, comprising 34 from John Hopkins Hospital (JHH) and 83 from Baskent University (BU), were treated with stereotactic ablative radiation therapy (SABR) MDT with both pre- and post-MDT PSMA-PET/CT scans acquired. PET radiomic features were analyzed from a CT-PET fusion defined gross tumor volume ((GTV) or zone 1), and a 5 mm expansion ring area outside the GTV (zone 2).
Clin Transl Oncol
June 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey.
Eur Urol Oncol
June 2024
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA. Electronic address:
Int J Radiat Oncol Biol Phys
July 2024
Department of Radiation Oncology, Adana Dr Turgut Noyan Research and Treatment Center, Başkent University Faculty of Medicine, Adana, Turkey.
Clin Nucl Med
August 2024
Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.
Adv Radiat Oncol
July 2024
Department of Radiation Oncology, The Mayo Clinic, Rochester, Minnesota.
Purpose: Emerging data suggest that metastasis-directed therapy (MDT) improves outcomes in patients with oligometastatic castration-sensitive prostate cancer (omCSPC). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) can detect occult metastatic disease, and PSMA response has been proposed as a biomarker for treatment response. Herein, we identify and validate a PSMA-PET biomarker for metastasis-free survival (MFS) following MDT in omCSPC.
View Article and Find Full Text PDFIn Vivo
April 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkey.
Background/aim: To compare implant sparing irradiation with conventional radiotherapy (RT) using helical (H) and TomoDirect (TD) techniques in breast cancer patients undergoing immediate breast reconstruction (IBR).
Patients And Methods: The dosimetric parameters of 40 patients with retropectoral implants receiving 50.4 Gy delivered in 28 fractions were analyzed.
Radiother Oncol
August 2024
Baskent University Faculty of Medicine, Department of Radiation Oncology, Ankara, Turkey; Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Adana, Turkey.
Prostate
June 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey.
Purpose: To compare the biochemical failure (FFBF) and prostate cancer specific survival (PCSS) rates of patients with intermediate-risk prostate cancer (IR-PC) who were treated with 6 months of androgen deprivation therapy (ADT) with 78 Gy to the prostate, those treated with ADT and focal boost (FB) of 86 Gy to intraprostatic lesion (IPL) using the simultaneous-integrated boost (SIB) technique, and those treated with SIB alone.
Materials And Methods: A retrospective analysis of 320 IR-PC patients treated between January 2012 and April 2021 was performed. Patients were divided into three groups based on their treatment arm: 78 + ADT (109 patients, 34.
Clin Transl Radiat Oncol
March 2024
Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Department of Radiation Oncology, Adana, Turkey.
Eur Urol Oncol
June 2024
Department of Radiation Oncology, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, Turkey.
Urol Oncol
April 2024
Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkey.
J Appl Clin Med Phys
January 2024
Faculty of Medicine, Department of Radiation Oncology, Baskent University, Ankara, Turkey.
Background: We examined the effects of reducing the planning target volume (PTV) margin in MR-guided radiotherapy (MRgRT) on the distribution of radiation dose to target volumes and organs-at-risk (OARs). Thus, we compared MR-Linac (MRL) plans with and without reduced margin and intensity-modulated radiotherapy (IMRT) plan with conventional linac for low-risk prostate cancer patients receiving 36.25 Gy in five fractions of ultra-hypofractionated radiation therapy.
View Article and Find Full Text PDFRep Pract Oncol Radiother
August 2023
Department of Radiation Oncology, Baskent University Faculty of Medicine Adana Dr Turgut Noyan Research and Treatment Center, Adana, Türkiye.
Background: The aim of the study was to perform dosimetric comparisons of helical (H) and TomoDirect (TD) plans for whole-breast irradiation (WBI) with simultaneous integrated boost (SIB) in early-stage breast cancer patients undergoing breast conserving surgery.
Materials And Methods: Fifty patients, 25 with left-side and 25 with right-side tumors, were determined for a treatment planning system for a total dose of 50.4Gy in 1.
Eur J Nucl Med Mol Imaging
October 2023
Department of Nuclear Medicine, Baskent University Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkey.
Purpose: We examined the prognostic significance of early changes in primary tumor SUV measured with Gallium-68-labeled prostate-specific membrane antigen positron emission tomography ([Ga]Ga-PSMA-11-PET/CT) and serum PSA values after neoadjuvant androgen deprivation treatment (nADT) in high-risk prostate cancer (PCa) patients treated with definitive radiotherapy (RT).
Methods: The clinical data and SUV parameters of 71 PCa patients were reviewed retrospectively. The serum PSA and primary tumor SUV values were calculated before and after the start of ADT.
Oncol Res
June 2023
Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana Dr. Turgut Noyan Research and Treatment Center, Adana, Turkey.
The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses.
View Article and Find Full Text PDFProstate
September 2023
Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey.
Background: To evaluate the treatment outcomes and toxicity of definitive radiotherapy (RT) for prostate cancer (PC) patients using the simultaneous integrated boost (SIB) technique, which delivered 78 Gy to the entire prostate and 86 Gy to the intraprostatic lesion (IPL) in 39 fractions.
Materials And Methods: Univariable and multivariable analyses were conducted of the prognostic factors for freedom from biochemical failure (FFBF), progression-free survival (PFS), and PC-specific survival (PCSS) of 619 PC patients who received definitive RT between September 2012 and August 2021. Predictors of late Grade ≥2 genitourinary (GU) and gastrointestinal (GI) toxicities were also identified using logistic regression.
Int J Gynecol Cancer
May 2023
Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkey
Objective: To investigate the prognostic factors for survival and toxicities in elderly (≥65 years) patients with endometrial cancer who underwent post-operative radiotherapy. Additionally, to compare the treatment outcomes between the older elderly (≥75 years) and younger elderly (65-74 years) patients.
Methods: Medical records of patients with enometrial cancer treated between January 1998 and July 2019 were reviewed.